Detta är en fortsättning på samtalet som inleddes vid Folkhälsodalen den 21 april och som grundades på en färsk rapport beställd av Janssen. Enligt rapporten tycks patienters tillgång …

This ADR is authorized to distribute the products listed below 176 items found, displaying 51 to 100

This ADR is authorized to distribute the products listed below 168 items found, displaying 51 to 100

Janssen Pharmaceuticals, Inc. 2024 02/24 cp-420113v1 concerns about patients receiving SPRAVATO®. and current referring HCPs and keep track of communications that are sent to …

We look forward to sharing more with you about TREMFYA ® (guselkumab). In the meantime, if you have any questions, feel free to call a Janssen CarePath Care Coordinator at …

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured. A …

SPRAVATO® can cause serious side effects, including sleepiness (sedation); fainting; dizziness; spinning sensation; anxiety; or feeling disconnected from yourself, your thoughts, feelings, …

TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may …

Please see Indications and Important Safety Information, full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO®. Janssen Pharmaceuticals, Inc. …

Jul 25, 2018 · Along with other pharmaceutical companies, Janssen takes part of the responsibility here. Janssen’s selection process is transparent, and is based on HCPs’ …